Ming J. Poi, Ph.D.
Affiliations: | 2002 | Ohio State University, Columbus, Columbus, OH |
Area:
Biochemistry, Molecular BiologyGoogle:
"Ming Poi"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Ming-Daw Tasi | grad student | 2002 | Ohio State | |
| (Low-barrier hydrogen bonding in bovine pancreatic phospholipase A(2), and, Somatic INK4a-ARF locus mutations: A significant mechanism of gene inactivation in head and neck squamous cell carcinomas.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Li J, Vangundy Z, Poi M. (2020) Cisplatin Induced the Expression of () Oncogene in Human Oral Squamous Cancer Cell Lines. Anticancer Research. 40: 67-73 |
| Persaud AK, Li J, Johnson JA, et al. (2019) XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. Molecular Carcinogenesis |
| Poi MJ, Li J, Johnson JA, et al. (2019) A Single Nucleotide Polymorphism in Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research. 39: 67-72 |
| Poi MJ, Knobloch TJ, Li J. (2017) Deletion of RD(INK4/ARF) enhancer: A novel mutation to "inactivate" the INK4-ARF locus. Dna Repair. 57: 50-55 |
| Sborov DW, Canella A, Hade EM, et al. (2017) A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leukemia & Lymphoma. 1-9 |
| Cho YK, Sborov DW, Lamprecht M, et al. (2017) Associations of high-dose melphalan pharmacokinetics and outcomes in the setting of a randomized cryotherapy trial. Clinical Pharmacology and Therapeutics |
| Poi MJ, Li J, Sborov DW, et al. (2017) Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. Molecular Carcinogenesis |
| Himmel LE, Lustberg MB, DeVries AC, et al. (2016) Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie |
| Jamieson GC, Fox JA, Poi M, et al. (2016) Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs |
| Awan FT, Jones JA, Maddocks K, et al. (2016) A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. Annals of Hematology |